Dr. Ian Martins  Photo
Dr. Ian Martins
Edith Cowan University
Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc) with an H-index of 64, (ResearchGate STATs (27), Scopus Author ID: 7103152779/Mendeley STATS (21), UWA Research Repository (16). Scientist for The Science Advisory Board (USA) and an Academic with Academia.edu. The citations past 27 years have accumulated to >4584. Ian James Martins - Semantic Scholar https://www.semanticscholar.org/author/Ian-James-Martins/5258067. Semantic Scholar profile for Ian James Martins, with fewer than 50 highly influential citations RESEARCHGATE ANALYSIS: Ian J Martins | Ph D | Centre of Excellence for Alzheimer's Disease ...https://www.researchgate.net/profile/Ian_Martins2 under Ian James Martins’ name places publication RG score (> 96%) of international SCIENTISTS. ORCID CONNECTING RESEARCHER: Editorial Team www.macrothink.org/journal/index.php/jfs/about/editorialTeamBio/13511 Editorial Team. Ian James Martins. Ian James Martins Mail • http://orcid.org/0000-0002-2390-1501. Edith Cowan University, Australia. Prestigious Recognition of Lifetime Membership by International Agency for Standards and Ratings as Fellow for Diabetes, Medical Science (Nutrition). Winner (World Academic Championship -2017) in Diabetes and Medical Science (Nutrition). Certificates from various international conferences have been received in relation to anti-aging, health and disease. Keynote addresses at, Biomedicine 2018 (Osaka, Japan), Global Experts Meeting on Diabetes, Hypertension, Metabolic Syndrome 2018 (Melbourne, Australia), Immunology World 2018 (Amsterdam, Netherlands), Laboratory Medicine 2018 (Berlin, Germany), Innovate Pharma 2017 (Sydney, Australia), Innovate Neurology 2017(Sydney, Australia) World Diabetes and Endocrinology Summit-2017 (Dubai), Pharmacology and Ethnopharmacology 2016 (Chicago, USA) and AGHC 2016 (1st Plenary Speaker, Kaohsiung, Taiwan). Chair/Co-chair Sessions on Laboratory management, Cytogenetics, Clinical Microbiology, Diagnostic Laboratory Medicine etc, 13th Interantional Conference on Laboratory Medicine and Pathology, Berlin, Germany, June 25-26, 2018, Chairing Sessions on Vaccinology, Immunopathology, Immunotherapy, Immune Proteomics, Cancer and Tumour Oncology, 7th World Congress on Immunology, Amsterdam, Netherlands, April 19-20, 2018, Chair, Pipeline 1: Biotherapeutics for Diseases, Bit's 2nd International Congress of Biotherapy-2018 (Programme Committee Member), Chair, Innovate Conferences 2017, Chair/Co-Chair at congress World Gene Convention-2016 (Shanghai, China, Pharmacology and Ethanopharmacology 2016 (Chicago, USA), Annual World Congress of Diabetes-2014 (Haikou, China), World Gene Convention-2014 (Haikou, China). Research Activity Statistics have been provided by Publons with comparison to other researchers. Ian James Martins is now in the 98th percentile as assessed for Publons users by merit. Dr Ian Martins is a reviewer for approx. 47 journals over the past 5 years.
2nd International Conference on Nutraceuticals & Food Sciences
13th World Congress on Dementia and Alzheimer's Disease
CPD Accredited 2nd International Conference on Clinical Trials & Pharmacovigilance
2nd International conference on Cell and Gene Therapy
13th International Conference on Alzheimers Disease and Dementia
2nd International Conference on Pathology and Surgical Pathology
Research Interests
Anti-Aging, Global Health and Chronic Disease
Anti-Aging, Global Health and Chronic Diseases
Anti-Aging, Global Health and Chronic Disease
Anti-Aging, Global Health and Chronic Disease
Anti-Aging, Global Health and Chronic Disease
Anti-Aging, Global Health and Chronic Disease
Anti-Aging, Global Health and Chronic Disease
Interested in Chronic Diseases
IMPACT OF PREVIOUS RESEARCH TO THE FIELD OF MEDICINE AND LABORATORY TECHNOLOGY THAT MAY AVOID INADVERTENT ERRORS AND MAY TRANSLATE TO COMMERCIALISATION OF MEDICAL RESEARCH THAT DETERMINE CRITICAL HEATLH OUTCOMES. Development of a BLOOD TEST has been of critical interest to the QUALITY CONTROL of plasma/sera samples for metabolic disease with relevance to diabetes and neurodegenerative diseases. RELEVANT PUBLICATIONS: 1. Sirtuin 1, a Diagnostic Protein Marker and its Relevance to Chronic Disease and Therapeutic Drug Interventions”. EC Pharmacology and Toxicology 6.4 (2018): 209-215. CERTIFICATE OF PUBLICATION. 2. Evaluation of diagnostic tests in human health and disease. J Clin Path Lab Med. 2018;2(1):13-15. SIRTUIN 1 ANALYSIS ON BLOOD/PLASMA SAMPLES SHOULD BE CONDUCTED IN APPROPRIATE PRESERVATIVE, UNDER FREEZE/THAW CONDITIONS, STORAGE CONDITIONS. Bacterial LPS should be conducted (Sirtuin 1 repression) to avoid bacterial contamination with long term storage. ONLINE REFERENCES: 1. The Future of Genomic Medicine Involves the Maintenance of Sirtuin 1 in Global Populations. Int J Mol Biol. 2017. 2. The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease. Arch Infect Dis Ther. 2017. 3. Bacterial Lipopolysaccharides Change Membrane Fluidity with Relevance to Phospholipid and Amyloid Beta Dynamics in Alzheimer’s Disease. J Microb Biochem Technol. 2016. 4. The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease. Proteomes, 2016. 5. LPS Regulates Apolipoprotein E and A? Interactions with Effects on Acute Phase Proteins and Amyloidosis. Advances in Aging Research 2015. Dr Martins research with relevance to diet, diabetes and neurodegenerative diseases builds upon his past > 150 publications that generates outputs that will have relevant and significant impact to the global community. The incidence of diabetes and non alcoholic fatty liver disease (NAFLD) has been predicted to increase to 21% by 2050. Novel and critical elements of scholarly peer review provides information that the heat shock gene Sirtuin 1 is repressed with relevance to diabetes, neurological diseases and Alzheimer's disease. Major unsolved challenges to advances in biology may now provide evidence to reverse Sirtuin 1 dysfunction that is connected to primarily to heat shock protein metabolism and secondly to toxic amyloid beta metabolism with mitochondrial apoptosis in liver and brain cells. In the developing world increased levels of bacterial lipopolysaccharides repress the anti-aging gene Sirtuin 1 with the development of diabetes, neurodegenerative diseases and Alzheimer’s disease. Unhealthy diets accelerate Type 3 diabetes with the induction of NAFLD in Global Populations

Relevant Speakers

Upcoming Events
View All

Allied Academies Global Conference Directory

Copyright © 2019-2020 Allied Academies, All Rights Reserved.